KR102530871B1 - Alk 억제제로서의 아미노피리미딘 - Google Patents

Alk 억제제로서의 아미노피리미딘 Download PDF

Info

Publication number
KR102530871B1
KR102530871B1 KR1020197007075A KR20197007075A KR102530871B1 KR 102530871 B1 KR102530871 B1 KR 102530871B1 KR 1020197007075 A KR1020197007075 A KR 1020197007075A KR 20197007075 A KR20197007075 A KR 20197007075A KR 102530871 B1 KR102530871 B1 KR 102530871B1
Authority
KR
South Korea
Prior art keywords
phenyl
isopropoxy
isopropylsulfonyl
pyrimidine
diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197007075A
Other languages
English (en)
Korean (ko)
Other versions
KR20190039760A (ko
Inventor
샤오멩 왕
지안용 첸
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시건
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시건 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시건
Publication of KR20190039760A publication Critical patent/KR20190039760A/ko
Application granted granted Critical
Publication of KR102530871B1 publication Critical patent/KR102530871B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197007075A 2016-08-29 2017-08-28 Alk 억제제로서의 아미노피리미딘 Active KR102530871B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Publications (2)

Publication Number Publication Date
KR20190039760A KR20190039760A (ko) 2019-04-15
KR102530871B1 true KR102530871B1 (ko) 2023-05-09

Family

ID=59846649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197007075A Active KR102530871B1 (ko) 2016-08-29 2017-08-28 Alk 억제제로서의 아미노피리미딘

Country Status (11)

Country Link
US (2) US10709705B2 (https=)
EP (2) EP3504203B1 (https=)
JP (2) JP7094566B2 (https=)
KR (1) KR102530871B1 (https=)
CN (2) CN109715620B (https=)
AU (2) AU2017319135B2 (https=)
IL (1) IL264638B (https=)
MX (2) MX389265B (https=)
NZ (1) NZ751713A (https=)
SG (2) SG10201914030UA (https=)
WO (1) WO2018044767A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314625B2 (en) * 2018-07-31 2022-05-12 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
US20220117964A1 (en) * 2019-06-25 2022-04-21 Ascentage Pharma (Suzhu) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
CN115212311B (zh) * 2021-04-19 2024-08-09 苏州亚盛药业有限公司 一种药物组合及其用途
CA3238857A1 (en) * 2021-12-09 2023-06-15 Oncobix Co., Ltd. Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
JP2026508811A (ja) 2023-01-20 2026-03-13 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ａｌｋ阻害剤またはその塩、溶媒和物の結晶形態ならびにその製造方法および使用
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용
WO2025232723A1 (en) * 2024-05-06 2025-11-13 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with focal adhesion kinase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106540A1 (en) 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
NZ585188A (en) 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06003054A (es) * 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
US8592432B2 (en) 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BR112013008816A2 (pt) 2010-10-14 2016-06-28 Ariad Pharma Inc método de tratamento de câncer direcionado ao egfr resistente à erlotinibe ou gefitinibe, ou uso de um sal farmacêuticamente aceito em um indivíduo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106540A1 (en) 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
MX2019002393A (es) 2019-07-08
EP4001273A2 (en) 2022-05-25
MX2022000376A (es) 2022-02-10
US20200330464A1 (en) 2020-10-22
CN115043821A (zh) 2022-09-13
KR20190039760A (ko) 2019-04-15
EP3504203B1 (en) 2022-09-28
CN109715620B (zh) 2022-05-06
US20190175595A1 (en) 2019-06-13
CA3033223A1 (en) 2018-03-08
SG11201901251SA (en) 2019-03-28
WO2018044767A2 (en) 2018-03-08
NZ751713A (en) 2022-07-01
JP2019528307A (ja) 2019-10-10
JP7094566B2 (ja) 2022-07-04
US11110090B2 (en) 2021-09-07
MX389265B (es) 2025-03-20
AU2017319135B2 (en) 2021-03-18
SG10201914030UA (en) 2020-03-30
CN115043821B (zh) 2024-08-06
WO2018044767A3 (en) 2018-04-12
AU2017319135A1 (en) 2019-04-04
AU2021203098B2 (en) 2023-05-25
EP3504203A2 (en) 2019-07-03
CN109715620A (zh) 2019-05-03
JP2022120151A (ja) 2022-08-17
AU2021203098A1 (en) 2021-06-10
BR112019003897A2 (pt) 2019-05-21
EP4001273A3 (en) 2022-08-24
IL264638B (en) 2021-08-31
US10709705B2 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
KR102530871B1 (ko) Alk 억제제로서의 아미노피리미딘
US11192898B2 (en) MDM2 protein degraders
US11168082B2 (en) Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
CN110294750A (zh) 作为alk抑制剂的5,6-二氢-11h-吲哚并[2,3-b]喹啉-11-酮化合物
US20210115018A1 (en) Piperidine compounds as covalent menin inhibitors
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
AU2017363161B2 (en) 5,6-dihydro-11H-indolo[2,3-b]quinolin-11-ones as ALK inhibitors
HK40077976A (en) Aminopyrimidines as alk inhibitors
CA3033223C (en) Aminopyrimidines as alk inhibitors
HK40007649A (en) Aminopyrimidines as alk inhibitors
HK40007649B (en) Aminopyrimidines as alk inhibitors
HK40012150A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors
HK40077976B (zh) 作为alk抑制剂的氨基嘧啶
BR112019003897B1 (pt) Compostos de aminopirimidinas como inibidores de alk, composição farmacêutica bem como seus usos
HK40013399A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601